OOCYTE ACTIVATION · Oocyte activation and human infertility: Identification and characterisation of a critical oocyte-borne receptor, and effects of laboratory procedures upon key proteins involved in oocyte activation
FP7 — People (Marie Curie Actions)
- Duration
- 2014-04-01 → 2016-03-31
- EU contribution
- €299,558
- Participants
- 1
- Scheme
- MC-IEF
Lines connect the coordinator with its partners.
Results in brief
Oocyte activation and human infertility: Identification and characterisation of a critical oocyte-borne receptor, and effects of laboratory procedures upon key proteins involved in oocyte activation
The present project aimed at gaining new insights into the mechanisms underlying the activation of the mammalian oocyte. As widely known, mammalian oocytes are arrested at metaphase-II when ovulated and may only be released from this state when fertilised by a spermatozoon. Over years, the nature of the sperm protein accounting for oocyte activation was unknown and three different theories were proposed. However, over the last decade, mounting evidence has been supporting the crucial role of sperm-specific protein, phospholipase C ζ on the activation of the oocyte. In spite of this, other sperm proteins, such as post-acrosomal sperm protein (PAWP) have also been claimed to account for the activation of the oocyte. Because most of data supporting the role of PLCζ came from animal models, further research involving clinical samples was required. Against this background, the present project studied the presence and localization patterns of PLCζ in human sperm samples coming from fertile and non-fertile men, and found that the presence and localization patterns of PLCζ in human sperm are correlated to fertilisation rates following intracytoplasmic injection (ICSI). In contrast, proportions of sperm exhibiting PLCζ are not able to predict fertilising ability following conventional in vitro fertilisation (IVF). These data indicate that PLCζ may be used as a prognostic marker in specific cases of idiopathic infertility linked to male origin. This is a very important result, which emphasises the clinical relevance of this protein as the study conducted herein was that involved, thus far, the highest number of cases. Another part of the project was the study of how extrinsic and intrinsic factors could affect the localization patterns and expression of PLCζ. In this context, we found that iatrogenic damage could affect the localization of PLCζ. However, the most interesting result came from the evaluation of the relationship between advancing male age and expression and localization of PLCζ. While conventional spermiogram parameters such as motility were seen to be decreased concomitantly with advancing male age, no impact of age was observed on the proportions and expression of PLCζ. In conclusion, the present project has shown, by publishing their data in high impact factor journals, the relevance of the presence and localization patterns of PLCζ on the activation and fertilisation of the oocyte, and thus provides evidence for prognostic value of this protein. This may have a high impact upon the diagnostic tools of idiopathic infertility and may contribute to develop new therapeutic strategies for those men diagnosed with PLCζ deficiency. Given that, 1 in 7 couples suffer from infertility, the socio-economic impact of these findings is also high.
Data: CORDIS, © European Union
Project objective
Mammalian sperm activate the oocyte at fertilisation by triggering a calcium-mediated pathway via PLCζ, a sperm-specific phospholipase. PLCζ deficiency is linked to human infertility, a condition that affects 1 in 7 couples. While intra-cytoplasmic sperm injection (ICSI) can rescue many types of male infertility, 1 – 5% of cases fail due to PLCζ-deficiency. While artificial activating agents are available, such chemicals do not initiate activation in an endogenous manner. Recombinant PLCζ thus represents a safer therapeutic option. However, we do not yet know how PLCζ interacts with oocyte-based factors in order to regulate functionality. Current opinion is that an unidentified protein resides within the ooplasm upon vesicles containing the substrate for PLCζ. Identifying this factor, and optimising the manner in which oocyte activation deficiency (OAD) can be diagnosed and treated, is a key clinical remit. Of equal concern is that the host laboratory showed that clinical treatments, such as cryopreservation, can cause detrimental effect upon PLCζ in human sperm. Consequently, this proposal has two objectives: 1) identify the oocyte-factor that interacts with PLCζ via the use of protein-protein interaction technologies, and 2) evaluate the impact of clinical procedures upon gamete proteins that play a critical role during activation. Research will involve human gametes sourced from the Oxford Fertility Unit, along with murine and bovine animal models. The proposal is targeted to (a) improve our understanding of PLCζ function, (b) establish whether the oocyte-interacting protein represents a novel diagnostic marker for OAD, and (c) develop our understanding of how clinical procedures can influence proteins in human gametes. While the proposal is primarily targeted to human reproductive medicine, results will be equally applicable to animals of economic interest, such as the controlled breeding programmes used for equine and bovine species.
Original text from CORDIS.
Participants
- THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD · OxfordCoordinatorUnited Kingdom
Links
Data: CORDIS, © European Union
